menu
    • menu
    [{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Granisetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Kyowa Kirin \/ Cumberland Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kirin \/ Cumberland Pharmaceuticals"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Granisetron","moa":"5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cumberland Pharmaceuticals \/ Verity Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cumberland Pharmaceuticals \/ Verity Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Granisetron

    Menu

    Granisetron

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cumberland Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Cumberland Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Granisetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Verity Pharmaceuticals Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support ...

                            Details : Under the terms of that agreement, Cumberland acquired U.S. rights to Sancuso (Granisetron) and assumed full commercial responsibility for the product – including its distribution, marketing, promotion, manufacturing and medical support activities.

                            Brand Name : Sancuso

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 09, 2022

                            Lead Product(s) : Granisetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Verity Pharmaceuticals Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kyowa Kirin

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Kyowa Kirin

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Granisetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Cumberland Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cumberland Pharmaceuticals Acquires Sancuso® From Kyowa Kirin North America

                            Details : Under the terms of the agreement, Cumberland will acquire U.S. rights to SANCUSO (Granisetron) and will assume full commercial responsibility for the product - including its marketing, promotion, distribution, manufacturing and medical support activities...

                            Brand Name : Sancuso

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 04, 2022

                            Lead Product(s) : Granisetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Cumberland Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth